| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Q613057-5mg |
5mg |
期货  |
| |
| Q613057-25mg |
25mg |
期货 |
|
| 别名 | 喹哌嗪 |
|---|---|
| 英文别名 | BRN 0196945 | AB00053761_12 | DTXSID3046952 | Tocris-0629 | SPBio_001223 | SPBio_002773 | STL308727 | 1-(2-Quinolyl)piperazine | BPBio1_001393 | NCGC00024694-03 | Prestwick3_000617 | 2-(1-PIPERAZINO)QUINOLINE | 2-(1-Piperazinyl)quinoline | A827323 | KBio2 |
| 规格或纯度 | Moligand™ |
| 英文名称 | quipazine |
| 作用类型 | 激动剂 |
| 作用机制 | 5-HT 2A 受体激动剂；5-HT 2B 受体激动剂；5-HT 2C 受体激动剂；5-HT 3A 激动剂；5-HT 3AB 激动剂 |
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 2-piperazin-1-ylquinoline |
| INCHI | 1S/C13H15N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h1-6,14H,7-10H2 |
| InChi Key | XRXDAJYKGWNHTQ-UHFFFAOYSA-N |
| Smiles | C1CN(CCN1)C2=NC3=CC=CC=C3C=C2 |
| Isomeric SMILES | C1CN(CCN1)C2=NC3=CC=CC=C3C=C2 |
| PubChem CID | 5011 |
| 分子量 | 213.280 g/mol |
|---|---|
| XLogP3 | 1.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 3 |
| 可旋转键计数Rotatable Bond Count | 1 |
| 精确质量Exact Mass | 213.127 Da |
| 单同位素质量Monoisotopic Mass | 213.127 Da |
| 拓扑极表面积Topological Polar Surface Area | 28.200 Ų |
| 重原子数Heavy Atom Count | 16 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 225.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Chopek JW, MacDonell CW, Gardiner K, Gardiner PF. (2014) Daily passive cycling attenuates the hyperexcitability and restores the responsiveness of the extensor monosynaptic reflex to quipazine in the chronic spinally transected rat.. J Neurotrauma, 31 (12): (1083-7). [PMID:24484172] |
| 2. Dugan EA, Shumsky JS. (2015) A combination therapy of neural and glial restricted precursor cells and chronic quipazine treatment paired with passive cycling promotes quipazine-induced stepping in adult spinalized rats.. J Spinal Cord Med, 38 (6): (792-804). [PMID:25329574] |
| 3. Smith RL, Barrett RJ, Sanders-Bush E. (1995) Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.. J Pharmacol Exp Ther, 275 (2): (1050-7). [PMID:7473132] |
| 4. Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Bruni G, Romeo MR, Menziani MC et al.. (1998) Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.. J Med Chem, 41 (5): (728-41). [PMID:9513601] |
首页
400-620-6333
